Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

AstraZeneca Advances MedImmune's Benralizumab To Phase III In Severe Asthma

AstraZeneca (AZN.L,AZN: Quote) said it has begun the Phase III Windward programme for benralizumab, a potential treatment for severe uncontrolled asthma developed by MedImmune, the company's global biologics research and development arm. The aim of CALIMA, the first trial in the Windward programme, is to determine whether benralizumab reduces the number of exacerbations in patients with severe asthma that remains uncontrolled, despite receiving high doses of inhaled corticosteroids combined with a second controller like long-acting beta agonist.

Benralizumab is a monoclonal antibody binding to the interleukin-5 receptor, that depletes eosinophils, a type of white blood cell, which play a critical role in the cause and severity of asthma and asthma exacerbations. Emerging evidence demonstrates that for patients with elevated eosinophil counts, treatment with an IL-5 inhibitor in addition to guideline-based strategies may increase their asthma control and decrease the frequency of asthma attacks.

The CALIMA trial would evaluate the safety and effectiveness of benralizumab in actively reducing exacerbations in patients with uncontrolled asthma, and assess the benralizumab effect on lung function, asthma symptoms and other asthma control measures, as well as emergency room and hospitalisation rates due to asthma.

The efficacy and safety data from this trial supported the progression of benralizumab into our Phase III programme. These results are likely to be shared at a scientific conference in the first half of 2014. Benralizumab is in-licensed from BioWa, Inc., a subsidiary of Kyowa Hakko Kirin Co., Ltd.

Register
To receive FREE breaking news email alerts for AstraZeneca PLC and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Stocks moved notably higher over the course of the trading day on Monday, extending the strong upward move seen last Friday. The gains on the day continued the recent recovery by the markets, with the Nasdaq and the S&P 500 closing higher for the third consecutive session. While Republicans have largely tried to frame the upcoming midterm elections as a referendum on President Barack Obama, Sen. Ted Cruz, R-Tex., has joined the few offering guidance on what the GOP will do if it manages to retake control of the Senate. The World Health Organization (WHO) Monday declared that Nigeria is officially free of Ebola virus transmission. For the last six weeks, no new cases of the deadly virus infection has been reported in the country. The lines on the tabular situation reports, sent to WHO each day by its country office in Nigeria, have now been full of zeros for 42 days. If two incubation periods of 21 days pass
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.